Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9d0c82c6254d5b4bec8c96e45c9db7b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
filingDate |
2018-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d30476e3868a1b7f530b6cac727796ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_817beba61482bbd74086aa2393a21b2a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f3cb7efccea38c91878546a65d1f284 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36c45e93f59738b30f936e85e2c7ab78 |
publicationDate |
2019-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2019117148-A1 |
titleOfInvention |
Sulfonamide derivative or pharmaceutically acceptable acid-addition salt |
abstract |
The purpose of the present invention is to provide a novel low molecular-weight compound having orexin receptor agonist activity that is expected to be useful for the prevention or treatment of narcolepsy, etc. The present invention provides: a compound represented by formula (I) that has orexin receptor agonist activity (the symbols in the formula are the same as defined in the description) or a pharmaceutically acceptable acid-addition salt thereof; and an orexin receptor agonist comprising the compound or pharmaceutically acceptable acid-addition salt thereof. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022187231-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021065893-A1 |
priorityDate |
2017-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |